Response to brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: A critical appraisal

British Journal of Dermatology

Volumn 167, Issue 4, 2012, Pages 714-715

  Leonardi, C ^a  

^a Central Dermatology PC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BRODALUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; IXEKIZUMAB; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; USTEKINUMAB;

DISEASE SEVERITY; DRUG RESPONSE; HUMAN; NOTE; PRIORITY JOURNAL; PSORIASIS; RANDOMIZATION; SCORING SYSTEM; SCREENING;

EID: 84867019790     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12027     Document Type: Note

References (2)

1. Spuls PI, Hooft L,. Brodalumab and ixekizumab, anti-interleukin-17- receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol 2012; 167: 710-13.
2. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-9.